The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to explore the dual-dimensional early intervention strategy of standard of care combined with host immunomodulation in elderly patients with mild and moderate COVID-19.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huashan Hospital
• Treatments: Dexamethasone; Glucocorticoids; Methylprednisolone; Prednisone

Criteria

Inclusion Criteria:

• Age ≥ 65;

• Male or female;

• Positive test for coronavirus antigen or nucleic acid；

• Within 7 days of onset (fever and/or cough) and Continuous high fever (> 39 °C) > 24h；

• mild and moderate；Mild: respiratory tract infection is the main manifestation, such as dry throat, sore throat, cough, fever；Moderate: continuous high fever>3 days or (and) cough, shortness of breath, etc., but respiratory rate (RR)<30 times/minute, oxygen saturation>93% when breathing air at rest. Imaging findings of characteristic pneumonia caused by COVID-19 infection；

• The patient is willing to participate in the trial treatment and follow-up, and sign the informed consent form (if the patient lacks the ability to give informed consent due to his serious medical condition, such as acute respiratory failure or the need for respiratory support, he can obtain the consent of the patient's legal representative)；

• No glucocorticoid treatment in the past 7 days；

Exclusion Criteria:

• Serious and uncontrolled comorbidities；

• Expected lifetime is less than 1 month；

• Severe/critical;

• Other situations that are evaluated by researchers as not suitable for participating the study.

Criteria for discontinuation

• The subject could not benefit after treatment (discontinued patients could be analyzed according to the PP analysis set);

Withdrawal criteria (if any of the following items are required)

• The subject asked to withdraw from the study;

• The subject needs to withdraw from the study after clinical observation after discontinuing treatment;

• The subject died or lost to follow-up.